Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Scorpius Holdings Inc (EM) SCPX

Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company serves the biotechnology and biopharmaceutical industries. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in San Antonio, Texas.


EXPM:SCPX - Post by User

User Avatar Image
(159)
•••
  • TanzaniteMotherLodeX
Post by TanzaniteMotherLodeon Mar 10, 2020 7:02am
475 Views
Post# 30787090

Another good yahoo post

Another good yahoo postHeat Biologics is not just a CV play. Even without that massive upside opportunity for shareholder value, the partnership with Bristol Myers Squib on small cell lung cancer is progressing is very promising as it goes to phase 2 trials. I wouldn't be surprised if this is bought out soon just for their proprietary technology. The TCAP - t-cell activation platform is fast, cost effective and through their technology - the solutions are fully scalable and off-the shelf is the desired route for quick treatment and ramping supply to meet demand. Their solutions impact cancer, sars type viruses, malaria defence etc. I see a number of vaccines hitting the market over the years and this is a very attractive buyout candidate (although I prefer they keep going it on their own to maximize shareholder value for true longs).
the management team is proactive and will be out in investors conferences like New York in just under 3 weeks, as well as on TV and other press. The collaboration with the University of Miami will be on the forefront.
the ceo built a company - TyrxPharma which was soldto Medtronic in the past. this is a solid long term investment.
<< Previous
Bullboard Posts
Next >>